What Are Components And Mechanism Action of Antibody-Drug Conjugates

by Sunny Fang on Dec 22, 2021 Finance 480 Views

Antibody-Drug Conjugates (ADC) is a type of anticancer drug that links a drug to cancer-targeting antibodies. The antibody detects tumor-specific proteins expressed on cancer cells and directs the cytotoxic anticancer drug towards the cancer cell.
 
Compared to alternative cancer treatments, for example, chemotherapy, immunotherapy, radiation, and stem cell therapy, ADC combines chemotherapy and immunotherapy and allows selective delivery of anticancer drugs and reduces systemic exposure and toxicity of anticancer drugs.
 
Components of ADC
 
One of the key requirements of ADC is the ability of monoclonal antibodies (mAb) to recognize tumor markers. These are unique antigenic markers highly expressed on cancer cells but are not found or in a low level of expression on normal, healthy cells.
 
For example, the HER2 (human epidermal growth receptor 2) receptor is expressed in cancer cells 100-fold higher than normal cells.  Moreover, the markers should possess internalization properties that allow the ADC to be transported into the cancer cell upon binding. This enhances the ability of the drug to perform cancer-killing activities.
 
The mAb component of ADC is important and should fulfill several requirements: it should have high specificity and binding affinity to the target tumor marker. This ensures the mAb only targets cancer cells. The mAb should also have low immunogenicity and no cross-reactivity. In the first and second generation of ADCs, the mAb is a chimera of human and mouse antibodies.
 
Despite its high efficacy, it sometimes generated an immune response in the human body against the mouse component of the antibody. Because of this, third-generation ADC employs fully human antibodies, and these are used to treat cancers such as HER-2–positive metastatic breast cancer.
 
The cytotoxic payloads are another important component of ADC: it is the cancer cell-killing drug that is linked to the mAb. The cytotoxic payload is stable and non-toxic when linked to the ADC and is activated once cleaved from the ADC inside the cytoplasm of cancer cells. There are 2 main drug classes used in ADC: microtubule-disrupting agents and DNA-damaging agents.
 
Mechanism of action
 
ADC is administrated intravenously into the bloodstream to avoid linker cleavage by acid and enzymes in the digestive system. Upon recognition of the mAb component to tumor-specific markers, ADC is internalized into cancer cells via receptor-mediated endocytosis.
 
Environmental changes such as low pH in the endosome and the presence of lysosomes inside the cell trigger the release of the cytotoxic payload of ADC. When released, the cytotoxic payload interferes with cellular mechanisms and induce programmed cell death – apoptosis.
 
Resistance to ADC
 
Although ADC provides a highly specific, low immunogenic cancer therapy, cancer cells that are pressured to survive ADC treatment lead to resistance to ADC. Resistance can be acquired, or cancer cells can be intrinsically resistant to different components of the ADC.
 
Tumour marker-related resistance can be due to decreased expression levels of the markers or masking of the marker with the extracellular matrix. Also, the upregulation of drug efflux pumps can expel cytotoxic payload from the cytoplasm of cancer cells. This limits the clinical success of ADC.
 
Future perspectives
 
As one of the research and development hotspots in the field of medicine, more than 100 ADCs are currently in different stages of clinical development, and there are hundreds of ongoing clinical trials.
 
To date, a total of twelve ADCs have been approved by the FDA, including: Kadcyla, Adcetris, Besponsa, Mylotarg, Lumoxiti, Polivy,Padcev, Trodelvy, Enhertu, Blenrep , ZYNLONTA, and Tivdak.
 
All in all, ADC is a promising therapeutic approach to treating cancers and is being constantly improved and developed.
 
Biopharma PEG, as a professional PEG derivatives supplier, is dedicated to being your most reliable partner to provide chemical synthesis and high-quality PEG linkers. We are committed to promoting the progress of yourADC discovery and development projects. 

Article source: https://article-realm.com/article/Finance/18009-What-Are-Components-And-Mechanism-Action-of-Antibody-Drug-Conjugates.html

Comments

No comments have been left here yet. Be the first who will do it.
Safety

captchaPlease input letters you see on the image.
Click on image to redraw.

Reviews

Guest

Overall Rating:

Most Viewed Articles

Statistics

Members
Members: 17030
Publishing
Articles: 79,426
Categories: 202
Online
Active Users: 2769
Members: 8
Guests: 2761
Bots: 26169
Visits last 24h (live): 6172
Visits last 24h (bots): 55071

Latest Comments

나는 그들이 매우 도움이 될 것이라고 확신하기 때문에 사람들을 귀하의 사이트로 다시 보내기 위해 귀하의 사이트를 내 소셜 미디어 계정에 추가하고 공유했습니다. 짱구카지노  
나는이 웹 사이트에있는 당신의 몇몇 포스트를보고 있었다. 그리고 나는이 웹 사이트가 정말로 유익하다고 생각한다! 계속 ..   푸우벳    
나는 그들이 매우 도움이 될 것이라고 확신하기 때문에 사람들을 귀하의 사이트로 다시 보내기 위해 귀하의 사이트를 내 소셜 미디어 계정에 추가하고 공유했습니다.   개미카지노    
"이것은 훌륭한 기사입니다. 많은 정보를 감안할 때 이러한 유형의 기사는 사용자의 웹 사이트에 대한 관심을 유지하고 계속해서 더 많은 정보를 공유합니다. 행운을 빕니다.   푸우벳    
" '훌륭한 유용한 리소스를 무료로 제공하는 가격을 알 수있는 웹 사이트를 보는 것이 좋습니다. 귀하의 게시물을 읽는 것이 정말 마음에 들었습니다. 감사합니다! 훌륭한 읽기, 긍정적 인 사이트,이 게시물에 대한 정보를 어디서 얻었습니까? 지금 귀하의 웹 사이트에서 몇 가지 기사를 읽었으며 귀하의 스타일이 정말 마음에 듭니다. 백만명에게 감사하고...
"여기에 제공해 주신 귀중한 정보와 통찰력에 감사드립니다 ...  세븐벳    
인터넷을 검색하다가 몇 가지 정보를 찾고 있던 중 귀하의 블로그를 발견했습니다. 이 블로그에있는 정보에 깊은 인상을 받았습니다. 이 주제를 얼마나 잘 이해하고 있는지 보여줍니다. 이 페이지를 북마크에 추가했습니다. 띵카지노  
아주 좋은 블로그 게시물. 다시 한 번 감사드립니다. 멋있는.   개미카지노    
귀하의 블로그가 너무 놀랍습니다. 나는 내가보고있는 것을 쉽게 발견했다. 또한 콘텐츠 품질이 굉장합니다. 넛지 주셔서 감사합니다! 텐텐 도메인 공식 주소  
The Tigernut Milk Market is such an interesting niche to follow, especially as more people explore dairy-free and naturally sweet alternatives. I like how tigernut milk offers a different profile...
on Sep 15, 2026 about Tigernut Milk Market

Translate To: